ask why

Latest research

Every new paper in 280 characters, with how strong the evidence is and what readers question about it. Free to read.

Respiratory · Eur Respir J · 2026-10-09

RCT in 51 children and adolescents (6–20 y) with post-infectious bronchiolitis obliterans: 16 weeks of home, remotely supervised HIIT vs activity advice raised VO2 peak (MD 3.39 mL/kg/min; p=0.04) and time to VT1 (1.05 min); other primary measures did not differ.

RCTn = 51
Salazar-Pérez et al. Home-based, remotely supervised, high-intensity interval training and cardiorespiratory fitness in children and adolescents with post-infectious bronchiolitis obliterans: a randomised controlled trial
Respiratory · Am J Respir Crit Care Med · 2026-10-01

ATS guideline update for children under 2 with interstitial lung disease: strongly recommends rapid broad genetic testing in infants with respiratory failure, surgical biopsy in defined situations and transplant referral for poor-prognosis disorders; chest CT conditional.

Guideline
McGraw et al. An update to the classification, evaluation, and management of childhood interstitial lung disease in infancy: an official American Thoracic Society Clinical Practice Guideline
Respiratory · Eur Respir J · 2026-09-25

ERS guideline (GRADE) on GLILD in CVID recommends screening all adults with CVID, preferably by high-resolution CT, multidisciplinary team evaluation, biopsy only for atypical cases, BAL to exclude infection, and gas transfer testing. Most recommendations are conditional.

Guideline
Bintalib et al. Clinical practice guideline for the diagnosis of granulomatous-lymphocytic interstitial lung disease in patients with common variable immunodeficiency disorders: an ERS Clinical Research Collaboration
Respiratory · Ann Am Thorac Soc · 2026-09-01

Single-centre target-trial emulation in 172 nintedanib initiators with fibrosing ILD: starting at 100 mg vs 150 mg twice daily was associated with 52.9 more days on treatment over 12 months and lower discontinuation risk (0.135 vs 0.281); FVC change was similar but imprecise.

RCTn = 172
Kaburaki et al. Low-dose vs standard-dose nintedanib at initiation in fibrosing interstitial lung disease: a target-trial emulation of treatment persistence and lung function

Sign in to react

Enter your email and we send a 6-digit code and a link. No password.

Your name and role

These appear beside any methods concern you post and on your profile page.